Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02805244 · ClinicalTrials.gov registry record · Phase 1
Mass Balance Study of JTZ-951 in Subjects With End-stage Renal Disease on Hemodialysis
A Phase 1 study, sponsored by Akros Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT02805244: Completed Phase 1 study, sponsored by Akros Pharma.
NCT02805244 is a Phase 1 study that has completed, run by Akros Pharma. The registered enrollment target is 6 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02805244, a Phase 1 study, has completed, sponsored by Akros Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
A mass balance study to determine the routes and rates of elimination of radioactivity, to determine total radioactivity in plasma and whole blood over time and compare levels to JTZ-951 and drug-derived entities in plasma and to determine pharmacokinetic (PK) parameters of JTZ-951 and its metabolite(s).
Interventions
- DRUG JTZ-951, 14C-JTZ-951
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2016-06 |
| Est. Completion | 2016-09 |
| Phase | Phase 1 |
What the finished NCT02805244 record still lists
NCT02805244 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 1 intervention - of which JTZ-951, 14C-JTZ-951 is the first listed.
NCT02805244 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02805244 about?
NCT02805244 is a clinical study titled "Mass Balance Study of JTZ-951 in Subjects With End-stage Renal Disease on Hemodialysis". A mass balance study to determine the routes and rates of elimination of radioactivity, to determine total radioactivity in plasma and whole blood over time and compare levels to JTZ-951 and drug-derived entities in plasma and to determine pharmacokinetic (PK) parameters of JTZ-951 and its metabolit...
What is the current status of trial NCT02805244?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2016-06. Estimated completion is 2016-09.
What interventions are being tested in trial NCT02805244?
The interventions under investigation include: JTZ-951, 14C-JTZ-951 (DRUG).
Who is sponsoring clinical trial NCT02805244?
This trial is sponsored by Akros Pharma, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02805244's enrollment target sits among peer trials
6 1974th of 2000 higher than 12 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia